Who Paid My Doc
Robert Wilson
Tampa, FL Doctor of Osteopathy
NPI 1912996489 CMS profile 1292280
2919 W Swann Ave, Suite 401, Tampa, FL 33609
General payments
$146
Research payments
$0
Ownership & investment interest
$0
Through program year 2024, Robert Wilson of Tampa, FL is reported in the CMS Open Payments database as having received $146 across 2 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $131 | 1 | |
| 2020 | General | $15 | 1 |
Beside peers
- Robert Wilson
- Florida median
- Middle half of Florida
- National median
In program year 2025, general payments to Robert Wilson were reported at $0. Among 84,641 Florida profiles paid that year, the median was $195 and the middle half received between $59 and $690.
Show as a table
| Year | Robert Wilson | Florida median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $197 | $63–$719 | $163 |
| 2020 | $15 | $126 | $38–$436 | $114 |
| 2021 | $0 | $151 | $45–$537 | $132 |
| 2022 | $0 | $175 | $53–$607 | $149 |
| 2023 | $0 | $183 | $57–$637 | $160 |
| 2024 | $131 | $185 | $56–$647 | $164 |
| 2025 | $0 | $195 | $59–$690 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 51 drugsPart D claims
2,174
Drug cost
$5,853,514
Branded share of claims
40.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 | Brand | 305 | $3,498,705 | |
| Gamunex-C Immune Globul G/Gly/Iga Avg 46 | Brand | 87 | $770,352 | |
| Gammaked Immune Globul G/Gly/Iga Avg 46 | Brand | 16 | $467,204 | |
| Firdapse Amifampridine Phosphate | Brand | 12 | $425,566 | |
| Privigen Immun Glob G(Igg)/Pro/Iga 0-50 | Brand | 34 | $403,021 | |
| Octagam Immun Globg(Igg)/Malt/Iga Ov50 | Brand | 19 | $99,728 | |
| Gammaplex Immun Glob G(Igg)/Gly/Iga 0-50 | Brand | 15 | $91,792 | |
| Oxycontin Oxycodone Hcl | Brand | 25 | $22,511 | |
| Droxidopa | Generic | 44 | $17,763 | |
| Pyridostigmine Bromide | Generic | 208 | $13,264 |
The 10 drugs with the highest cost, of 51 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 18 billing codesPaid by Medicare
$26,084
Medicare patients
163
Services billed
344
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 63% | |
| Arthritis | 55% | |
| Depression | 41% | |
| Ischemic heart disease | 32% | |
| Diabetes | 29% | |
| Chronic kidney disease | 28% | |
| COPD | 21% | |
| Heart failure | 18% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
2 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.